---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-044230"
form_type: "8-K"
ticker: null
cik: "0001463361"
company_name: "Unity Biotechnology, Inc."
filed_at: "2024-04-15T23:59:59+00:00"
generated_at: "2026-06-03T22:52:29.234641+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Unity Biotech reports FY 2023 net loss $39.9M; Phase 2b ASPIRE DME study upsized to 50 patients

## Summary
- Cash, equivalents and marketable securities $43.2M as of Dec 31, 2023; runway into Q3 2025.
- Net loss FY 2023 $39.9M (down from $44.5M in 2022); Q4 net loss $4.3M (down from $7.4M).
- R&D expenses decreased $16.8M to $20.1M in FY 2023 due to completion of BEHOLD/ENVISION studies and headcount reduction.
- Phase 2b ASPIRE study in DME (UBX1325 vs aflibercept) upsized to 50 patients; 16-week data expected Q4 2024, 24-week data Q1 2025.
- Published research in Nature Medicine in Jan 2024 on targeting cellular senescence in DME.

## SEC filing metadata
- accession: 0000950170-24-044230
- form_type: 8-K
- cik: 0001463361
- company_name: Unity Biotechnology, Inc.
- filed_at: 2024-04-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1463361/000095017024044230/0000950170-24-044230-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1463361/000095017024044230/ubx-20240415.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-044230
- JSON: https://secwatch.observer/filing/0000950170-24-044230.json
- Plain text: https://secwatch.observer/filing/0000950170-24-044230.txt

## Key facts
- Earnings Releases
  Unity Biotechnology, Inc. reported fourth quarter and full year ended December 31, 2023 results: net income Net loss for the twelve months ended December 31, 2023 was $39.9 million.
  - Period: fourth quarter and full year ended December 31, 2023
  - Net income: Net loss for the twelve months ended December 31, 2023 was $39.9 million
  - Result: reported results
  source text: On April 15, 2024, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1463361/000095017024044230/0000950170-24-044230-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.